Shanghai-based drug developer Antengene Corp. completed a $120 million series B financing, jointly led by Boyu Capital and FountainVest.
Celgene Corp., WuXi Corporate Venture Fund, Taikang, Qiming Venture Partners and TF Capital participated in the financing, Antengene said in a news release.
The company said it will use the funds to continue developing its lead programs ATG-008, a potential treatment for hematological malignancies and solid tumors, and ATG-010, also known as selinexor, a potential treatment for hepatitis B virus positive hepatocellular carcinoma.
Funds will also be used on Antengene's other clinical-stage assets, as well as expanding its pipeline, through internal research and development and external partnerships, and preparing the commercial launch of late-stage drug candidates.
Antengene is developing anti-cancer drug treatments for patients in China and Asia.